Search Results - "Mammoliti, S."

Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer by A. Gandini, V. Martelli, L. Belgioia, S. Puglisi, M. Cremante, V. Murianni, A. Damassi, C. Pirrone, F. Catalano, M. Grassi, L. Trevisan, S. Vagge, V. Andretta, S. Mammoliti, D. Comandini, G. Fornarini, A. Pessino, A. Pastorino, S. Sciallero, A. Puccini, A.F. Sobrero

“…Background: Patients with metastatic colorectal cancer (mCRC) carrying a deficit in the mismatch repair system/microsatellite instability (dMMR/MSI) show great…”
Get full text

First-line single-agent cetuximab in patients with advanced colorectal cancer by Pessino, A., Artale, S., Sciallero, S., Guglielmi, A., Fornarini, G., Andreotti, I.C., Mammoliti, S., Comandini, D., Caprioni, F., Bennicelli, E., Andretta, V., Siena, S., Sobrero, A.

“…Background: The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is active in heavily pretreated patients with metastatic colorectal cancer…”
Get full text

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies by Mammoliti, S., Andretta, V., Bennicelli, E., Caprioni, F., Comandini, D., Fornarini, G., Guglielmi, A., Pessino, A., Sciallero, S., Sobrero, A.F., Mazzola, G., Lambiase, A., Bordignon, C.

“…asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF), an agent selectively damaging the tumour vasculature, showed a biphasic dose–response…”
Get full text

Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients by Repetto, L., Comandini, D., Mammoliti, S.

“…With ageing, function preservation and maintenance of quality of life represent a major goal in an increasing proportion of patients. Life expectancy is a…”
Get full text

Haemorrhagic cystitis in haematopoietic stem cell transplantation (HSCT): a prospective observational study of incidence and management in HSCT centres within the GITMO network (Gruppo Italiano Trapianto Midollo Osseo) by Gargiulo, G, Orlando, L, Alberani, F, Crabu, G, Di Maio, A, Duranti, L, Errico, A, Liptrott, S, Pitrone, R, Santarone, S, Soliman, C, Trunfio, A, Selleri, C, Bruno, B, Mammoliti, S, Pane, F

“…Haemorrhagic cystitis (HC) is a recognised complication in patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). This study evaluates…”
Get full text

Is magnetic resonance imaging useful in early evaluation of women on neoadjuvant chemotherapy for locally advanced cervical cancer? by Sala, P, Marchiolè, P, Cittadini, G, Valenzano Menada, M, Moioli, M, Mammoliti, S, Costantini, S

“…To evaluate the accuracy of magnetic resonance imaging (MRI) in staging cervical tumors after neoadjuvant chemotherapy (NACT). 26 women, affected by locally…”
Get more information

Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: Preliminary results of a pilot study by Colombo, N., Mangili, G., Mammoliti, S., Kalling, M., Tholander, B., Sternas, L., Buzenet, G., Chamberlain, D.

“…Abstract only…”
Get full text

Pemetrexed disodium in ovarian cancer treatment by Morotti, M, Valenzano Menada, M, Venturini, P L, Mammoliti, S, Ferrero, S

“…Current therapies for recurrent ovarian cancer (OC) yield relatively modest improvements in survival. Many drugs are available but recently a renewed interest…”
Get more information

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest by Conte, P F, Bruzzone, M, Carnino, F, Gadducci, A, Algeri, R, Bellini, A, Boccardo, F, Brunetti, I, Catsafados, E, Chiara, S, Foglia, G, Gallo, L, Iskra, L, Mammoliti, S, Parodi, G, Ragni, N, Rosso, R, Rugiati, S, Rubagotti, A

“…The aim of the study was to compare high-versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin as primary chemotherapy for…”
Get more information

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial by Pignata, Sandro, Lorusso, Domenica, Joly, Florence, Gallo, Ciro, Colombo, Nicoletta, Sessa, Cristiana, Bamias, Aristotelis, Salutari, Vanda, Selle, Frédèric, Frezzini, Simona, De Giorgi, Ugo, Pautier, Patricia, Bologna, Alessandra, Orditura, Michele, Dubot, Coraline, Gadducci, Angiolo, Mammoliti, Serafina, Ray-Coquard, Isabelle, Zafarana, Elena, Breda, Enrico, Favier, Laure, Ardizzoia, Antonio, Cinieri, Saverio, Largillier, Rémy, Sambataro, Daniela, Guardiola, Emmanuel, Lauria, Rossella, Pisano, Carmela, Raspagliesi, Francesco, Scambia, Giovanni, Daniele, Gennaro, Perrone, Francesco, Pignata, S, Lorusso, D, Joly, F, Gallo, C, Colombo, N, Sessa, C, Bamias, A, Salutari, V, Selle, F, Frezzini, S, De Giorgi, U, Pautier, P, Bologna, A, Orditura, M, Dubot, C, Gadducci, A, Mammoliti, S, Ray-Coquard, I, Zafarana, E, Breda, E, Favier, L, Ardizzoia, A, Cinieri, S, Largillier, R, Sambataro, D, Guardiola, E, Lauria, R, Pisano, C, Raspagliesi, F, Scambia, G, Daniele, G, Perrone, F

“…Bevacizumab is approved in combination with chemotherapy for the treatment of ovarian cancer, either in first-line therapy or for patients with recurrent…”
Get full text

6075 A triple combination of Imatinib, Bevacizumab and Cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer by Pessino, A, Andretta, V, Guglielmi, A, Mammoliti, S, Caprioni, F, Fornarini, G, Comandini, D, Sciallero, S, Ansaldi, F, Sobrero, A

Get full text

597P Endometrial carcinoma and mismatch repair deficiency: Clinical association and universal screening for Lynch syndrome by Puglisi, S., Ponzano, M., Perachino, M., Pirrone, C., Damassi, A., Bregni, G., Puccini, A., Grassi, M., Trevisan, L., Gismondi, V., Dono, M., Lastraioli, S., Fedele, P., Cremante, M., Gandini, A., Giannelli, F., Mammoliti, S., Vellone, V.G., Sciallero, M.S., Iaia, M.L.

Get full text

590P Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancers: MITO 37 retrospective study by Tuninetti, V., Ghisoni, E., Pignata, S., Picardo, E., Raspagliesi, F., Andreetta, C., Maldi, E., Artioli, G., Mammoliti, S., Roccio, M., Sikokis, A., Biglia, N., Parisi, A., Mandato, V.D., Carella, C., Cormio, G., Marinaccio, M., Scotto, G., Di Maio, M., Valabrega, G.

Get full text

445TiP VIVA trial: A randomized phase II study of adjuvant regorafenib plus durvalumab in stage IV colorectal cancer patients achieving the no evidence of disease state by Pastorino, A., Puccini, A., Martelli, V., Grassi, M., Cremante, M., Gandini, A., Puglisi, S., Catalano, F., Murianni, V., Pessino, A., Andretta, V., Mammoliti, S., Sciallero, M.S., Comandini, D., Fornarini, G., Caprioni, F., Bregni, G., Barni, S., Labianca, R., Sobrero, A.F.

Get full text

50P Direct-acting oral anticoagulants prescribing pattern in patients with gynaecological cancer: Results of a survey among Italian oncologists belonging to MITO group and AIOM society by Tuninetti, V., Milani, A., Pignata, S., Lorusso, D., Castaldo, D., De Giorgi, U.F.F., Savarese, A., Biglia, N., Scandurra, G., Testa, S., Mangili, G., Di Maio, M., Turinetto, M., Mammoliti, S., Scotto, G., Artioli, G., Valabrega, G.

Get full text

Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer by SOBRERO, A. F, ASCHELE, C, BRUZZI, P, BERTINO, J. R, GUGLIELMI, A. P, MORI, A. M, TIXI, L. M, BOLLI, E. A, ROSSO, R, MAMMOLITI, S, ROLLANDI, G. A, BERTOGLIO, S

“…Based on experimental findings suggesting that 5-fluorouracil (FUra) may have different mechanisms of action depending on the schedule of administration, we…”
Get full text

Intraperitoneal Carboplatin with or without Interferon-α in Advanced Ovarian Cancer Patients with Minimal Residual Disease at Second Look: A Prospective Randomized Trial of 111 Patients by Bruzzone, M., Rubagotti, A., Gadducci, A., Catsafados, E., Foglia, G., Brunetti, I., Giannessi, P.G., Carnino, F., Iskra, L., Rosso, R., Martoni, A., Pannuti, F., De Lisi, V., Maltoni, R., Ridolfi, R., Mammoliti, S., Gallo, L., Boccardo, F., Ragni, N., Conte, P.F.

“…From June 1990 to October 1994, 111 advanced ovarian cancer patients with minimal (less than 2 cm) residual disease after platinum-based front-line…”
Get full text

66P PARPi and myeloid neoplasia: The Italian MITO-MaNGO experience based on a multicentric survey by Turinetto, M., Marchetti, C., Boccia, S.M., Scandurra, G., Colombo, N., Cormio, G., Savarese, A., De Angelis, C., Abeni, C., Petrella, M.C., Ferrero, A., Camnasio, C., Villa, F., Mammoliti, S., Giordano, M., Valabrega, G., Cirigliano, G., Destefanis, M., Scambia, G., Pignata, S.

Get full text

28P Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study by Tuninetti, V., Virano, E., Salutari, V., Ricotti, A., Pisano, C., Ducceschi, M., Turitto, G., Scandurra, G., Petrella, M.C., Forestieri, V., Rizzetto, M., Mammoliti, S., Artioli, G., Cioffi, R., Azzolina, C., Ferrandina, G., Pignata, S., Valabrega, G.

Get full text

Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients by MAMMOLITI, S, MERLINI, L, CAROTI, C, GALLO, L

“…We have carried out a phase II trial to evaluate the efficacy and toxicity of a combination therapy consisting of mitoxantrone 10 mg/sqm i.v. on day 1,…”
Get full text